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Abstract
The medical research facilitates to acquire a diverse type of data from the same
individual for a particular cancer. Recent studies show that utilizing such di-
verse data results in more accurate predictions. The major challenge faced is
how to utilize such diverse data sets in an effective way. In this paper, we intro-
duce a multiple kernel based pipeline for integrative analysis of high-throughput
molecular data (somatic mutation, copy number alteration, DNA methylation
and mRNA) and clinical data. We apply the pipeline on Ovarian cancer data
from TCGA. After multiple kernels have been generated from the weighted sum
of individual kernels, it is used to stratify patients and predict clinical outcomes.
We examine the survival time, vital status, and neoplasm cancer status of each
subtype to verify how well they cluster. We have also examined the power of
molecular and clinical data in predicting dichotomized overall survival data and
to classify the tumor grade for the cancer samples. It was observed that the
integration of various data types yields higher log-rank statistics value. We were
also able to predict clinical status with higher accuracy as compared to using
individual data types.
1 Introduction
Cancer is a disease with extreme complexity which alters the function of combi-
nations of genes. It is believed to be an outcome of accumulated genetic changes
[1]. Among various types of cancer, ovarian cancer is the fifth most common
cancers diagnosed in females [25] with overall five-year survival rate only around
44%[4]. The Cancer Genome Atlas (TCGA)[34] reports diverse genomic infor-
mation with paired clinical information for more than 500 cases of ovarian serous
cystadenocarcinoma. The genomic information includes copy number alteration
(CNA), somatic mutation, gene expression, and DNA methylation. Understand-
ing the genetic changes in cancer patients through this rich information allows
for better diagnostics and treatment of cancer, including ovarian cancer.
Integrative analysis of multiple perspectives of a patient helps in both patient
stratification and clinical outcome prediction. Patient stratification and clinical
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outcome predictions both help the researchers in understanding and exploring
the genomic characteristics in a relationship with their current phenotypes and
thus to recognizing opportunities for clinical improvement. In the case of cancer
data analysis, including ovarian cancer data, an improved stratification and
clinical prediction can be achieved by integrative analysis of the multiple bio-
clinical data. However, due to the complex relationship between the multiple
data types, the integrative analysis is still a challenging task.
There are several works related to clinical outcome predictions. Wang et al.
[39] have used gene expression data to predict distant metastasis of lymph-node-
negative primary breast cancer. They identified a 76-gene signature consisting
of 60 genes for patients positive for estrogen receptors (ER) and 16 genes for ER-
negative patients. Teschendorff et al. [33] proposed a gene expression classifier
for ER positive breast cancer. Zhang et al. [45] used copy number alterations in
combination with gene expression to identify the genomic loci and their mapped
genes, having a high correlation with distant metastasis capability of human
breast cancer. Deneberg et al. [8] used gene specific and global methylation
patterns predict outcome in patients with acute myeloid leukemia. They also
concluded in their work that global and gene specific methylation patterns are
independently associated with the clinical outcome in AML patients. Nair et
al. [21] reported a comprehensive review on the clinical outcome prediction by
the miRNA expression for numerous types of cancer. These approaches only
integrated a smaller number of data types and failed to integrate with other
levels of genomic data.
On the other hand, for the patient stratification, biomarkers, genetic pro-
files, research data along with clinical information are used to find a subgroup of
the patients thereby making easier to detect and interpret relationships as well
as predict outcomes in a specific subgroup. Kim et al.[14] considers somatic
mutation profile and exploited k-means clustering to identify the tumor sub-
types. The sparsity of the mutation data was handled by applying Jaccard and
Euclidean distance measures. Further, the Cox proportional hazards regression
model was used to find the similarity between the derived subtypes and the
patient survival time. In their recent work [15], a compressed somatic mutation
profile was suggested for fast comparison. The profile utilized Gene-Ontology
and non-negative matrix factorization for condensing the mutation profile. To
verify their work, stratification was performed on various cancer types. Hofree
et al. [11] has used genome-scale somatic mutation profiles in combination with
a gene interaction network to carry out subgrouping of patients. Recently, Wang
et al.[38] proposed a modified consensus clustering to carry out patient stratifi-
cation for breast cancer patients. The approach considered both numerical and
categorical data for mRNA and miRNA data set.
Analysis of one or few data types may not be sufficient for accurate predict
or stratification. Thus, efforts to integrate the molecular data were carried out.
Thomas et al.[36] work presents two general class of heterogeneous data inte-
gration, i.e., Multiple Kernel learning and Bayesian network, are detailed and
discussed in the bioinformatics domain. Also, many problem-specific integrative
approaches have been proposed to associate the molecular data with the clini-
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cal outcome. These include a software package implemented in R [19] to show
the effect of DNA methylation and copy number alterations in gene expression
of several known oncogenes for two cancer type glioblastoma multiforme and
ovarian. Kim et al. [13] proposed a graph based integrated framework using
CNA, methylation, miRNA, and gene expression data to carry out a molecular
based classification of clinical outcomes. In this approach, a single graph was
constructed by determining the optimum linear combination coefficient from
the multiple graphs obtained at different genomic level. Sohn et al. [29] mod-
eled the influence of multi-layered genomic features on gene expression traits by
modeling an integrative statistical framework based on a sparse regression. The
results showed that using CNA, miRNA, and methylation on gene expression in
the predictive power for gene expression level is improved over a single data type
based analysis. Schafer et al. ([26] approach integrated copy number and gene
expression by a modified correlation coefficient and an explorative Wilcoxon
test to find DNA regions of abnormalities. The recent work also includes model
based prediction of clinical outcomes. Mankoo et al. [20] have applied multi-
variate Cox Lasso model and median time-to-event prediction algorithm on data
set integrated from the four genomic data types (CNA, methylation, miRNA,
and gene expression data). Yuan et al. [43] evaluated the predictive power of
patient survival and binary clinical outcome using clinical data in combination
with one molecular data: somatic copy number alteration, DNA methylation,
and mRNA, miRNA and protein expression. They showed a slight improvement
in some cases when clinical information was combined with one of the molecular.
Although this paper showed the predictive power of clinical data in combination
with a molecular data, all available molecular data was not used integratively.
An integrative analysis method that can cover heterogeneity of data types in
molecular data and clinical data can beneficial in predicting the prognostics of
patients via stratifying the patients in the different risk groups. Multiple kernel
learning is well known for addressing various data heterogeneity. Moreover,
Kernel methods, including multiple kernels, are well-suited for handling non-
linearity of high dimensional data by mapping data to feature space [5].
In this paper, we make the following contributions:
• Combines clinical data with multiple molecular data. We examine
how adding more molecular information increases the prediction perfor-
mance in stratifying ovarian cancer patients, and predicting tumor grade
and patient survival time.
• Propose a multiple kernel based pipeline model (Fig. 1) to in-
tegrate multiple heterogeneous data types. The proposed model
allows to analyze heterogeneous data i.e., combines data with diverse back-
ground distributions, relations, dimensions, and formats to enhance the
statistical significance and thus, obtain more refined information.
• Propose the data pre-processing using patient-centered gene set
analysis. It allows to handle the large heterogeneous tumor data by
grouping them into much smaller set of pathways and biologic processes.
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Figure 1: Multi kernel learning based integrative pipelined model
2 Material and methods
2.1 Datasets and Raw Mutation Scores
Data are initially selected and downloaded 312 samples that contained all four
genomic data types, i.e., copy number alternation, methylation, mRNA expres-
sion and the mutation information, from TCGA data portal [32] via TCGA
assembler [46] and TCGA Firehose [6]. The summary of the genomic data
types and number of associated genes for each data type in the 312 samples are
shown in Table 1. Clinical information of the 312 samples is also downloaded
from TCGA. The clinical data includes the survival time (days to death), age,
tumor stage, tumor grade, vital status and neoplasm cancer status.
Table 1: Numbers of samples and features of data types for OV cancer.
Data Type Platform #Genes
altered in
312 patient
Union of
considered
genes
Methylation Illumina Human Meth. 13772 13772
CNA Agilent 1M 16383 16070
mRNA expression AgilentG4502A 18361 16070
Mutation WUSM 9039 9039
Description of the data types and how each is further processed are pro-
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vided in the following. For each DNA methylation sample, the percent signal
that is methylated is described as beta value recorded for each sample locus.
The beta values are continuous variables that range between 0 and 1 indicating
the ratio of the intensity of the methylation [18]. After downloading level three
data from TCGA assembler [46], the data is pre-processed and determined to
be methylated, if they show a percentage of methylation (beta) greater than
a certain threshold ( 0.3 for patient data) or unmethylated if the value falls
below the threshold as discussed by Warden et al. [40]. Thus, the new data
matrix constructed for the methylation has a score of 1, if a gene is methylated
else set to 0. The level three data for copy number alternation (CNA) was ob-
tained from the GISTIC [3] analysis. GISTIC identifies genomic regions that
are significantly gained or lost across a set of tumors. It contains data about
the significant regions of amplification and deletion as well as which samples are
amplified or deleted in each of these regions. The matrix element with a value
of 0 indicates no amplification or deletion above the threshold. Amplifications
are positive numbers: 1 denotes amplification above the amplification threshold;
2 denotes amplifications larger to the arm level amplifications observed for the
sample. Deletions are represented by negative table values: -1 represents dele-
tion beyond the threshold; -2 represents deletions greater than the minimum
arm-level deletion observed for the sample. The data matrix generated from
CNA data puts 1 if the gene is amplified or deleted and 0 if otherwise. The
dataset downloaded for level 3 mRNA from TCGA Firehose [6] contains log2
ratio for the gene expression.The log2 ratio ranges from 0 to 16, representing
relative gene expression levels. The level 2 somatic mutation data download
from TCGA is already in the required matrix format with the entries showing
either 0 or 1 indicating the presence or absence of a mutation in the gene.
2.2 Gene Sets and Adjusted Mutation Scores
We group the genes based on involvement in the same pathway or having the
similar molecular signature, thus some of the genes that do not fall in these
categories were filtered out. The total number of genes considered in this study
are summarized in the last column of Table 1.
Considering gene set takes into account the fact that genes do not act in
isolation, but they interact with other genes through the complex system. Also,
cancer occurs not in a single gene, but rather, a group of genes that interact
amongst each other in the complex biological network [14, 15]. Moreover, the
biological significance can be better analyzed by considering the interaction
between neighboring genes. For the different data sources, this measure helps
to construct a patient to geneset matrix containing the genomic information. We
have considered the functional group information of genes initially downloaded
from the Molecular Signatures Database (MSigDb) [30] and recreated to remove
redundancy. In the MSigDB, we select the group information based on pathway
(C2: 4722 gene sets) and based on motif (C3: 836 gene sets). MSigDB contains
gene sets generated from KEGG [12], Canonical Pathway [17], BIOCARTA [23]
and REACTOME [7]. The motif gene set contained in MSigDB are miRNA
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targets (MIR) and transcription factor target (TFT).
We recreate the gene sets to generate unified gene groups with small overlaps
while maximizing the number of genes covered. We filter out the gene sets with
more than 85% overlap as described in Algorithm 1. After filtering, 2099 gene
sets remained and the gene sets cover 16070 genes out of the initial 16095 genes.
Data: Gene sets in C2 and C3
Result: Selected gene set in F
S = {all sets in C2 and C3 ordered by number of genes in the gene set,
smallest to largest}
F = {} // empty set
foreach s1 in S do
SimSet = 0
foreach s2 in S - {s1} do
dist = (s1 ∩ s2) / (s1 ∪ s2) // Jaccard similarity
if dist ¿ 0.85 then
SimSet++;
end
end
if SimSet == 0 then
put s1 to F
end
delete s1 from S
end
Algorithm 1: Gene set selection.
Generated patient-to-gene set matrix contains gene sets as a new feature
vector, where each entry is an aggregating value of the altered genes in the gene
set.
2.3 Kernel Matrix Representing Molecular Information
The patient-to-gene set matrixes of the four data sources are used to create
kernels using kernel functions. A feature function, φ(x), maps the original data
feature x in the input space to a high-dimensional feature space. A Kernel
function is a function that corresponds to the inner product in a expanded
feature space: k(xi,xj) =< φ(xi) · φ(xj) >. A kernel matrix is formed by
computing kernel functions between all pairs of data. Thus, the size of a kernel
matrix is independent of the number of features and is solely dependent on the
number of data. In practice, an explicit definition of feature function, φ(x),
is not needed since they are tightly integrated into the definition of the kernel
functions.
The kernel functions we used are linear and radial basis function (RBF).
Details of linear and RBF kernels are as follows: Let ith and jth sample data be
represented as vectors of adjusted mutation scores of each gene sets: xi and xj .
A linear kernel of two samples is a dot product of their original feature vectors,
xi and xj :
klinear(xi,xj) =< xi · xj > .
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A RBF kernel of two samples vectors xi and xj is defined as follows:
kRBF (xi,xj) = exp(−||xi − xj ||2/2σ2),
where ||xi − xj ||2 is the squared Euclidean distance between the two original
feature vectors and parameter σ controls the flexibility of the kernel. With
smaller value for the parameter σ, the kernel matrix becomes closer to identity
matrix while risking overfitting. On the other hand, larger values of parameter
gradually reduce the kernel to a constant function, making it impossible to learn
any non-trivial classifier [28]. In our experiment, we use a separate validation
data sets consisting of 25% of total samples to determine the parameters of the
kernels, such as the value of σ in RBF kernels. The choice of the kernel for
different data sources is decided based on the existing study in the literature.
We explored the use of commonly used kernels including linear, sigmoid,
polynomial and the radial basis function. We chose the kernel function that
showed the best performance for each data type. For mRNA, we select RBF
kernel as in [9], the authors report in their work that the use of RBF kernel
proved to be more effective as compared to linear, polynomial or other kernels.
For a different combination of geneset, an accuracy of 92.59 % was observed.
The methylation data analysis [44] shows that the use of SVM classifier with
RBF kernel outperforms the k-nearest neighbor classifier (k-NN) and a naive
Bayes classifier with an accuracy of 91.3 %. In [37], the performance of RBF
kernel is compared to the clinical kernel for the clinical data source. Out of the
five case study carried out, it was observed that the RBF kernel outperforms
clinical in three with an average accuracy of 78.59 %. In the case of CNV, we
apply linear kernel, similar to [27] which uses linear kernel for CNV data source
for classification and attain an accuracy of 61%. For mutation data source, we
apply RBF kernel, as in [24] presents a detailed comparison result for linear,
polynomial and RBF kernel functions for breast cancer mutation data. It is
reported that the use of RBF kernel for classification achieved a higher accuracy
as compared to other kernels. For BRCA1-BRCA2 dataset, RBF attained an
accuracy of 100% as compared to 93.3% (linear) and 86.6 % (polynomial).
2.4 Multiple Kernel Learning for Cancer Classification
The kernel matrix constructed from each data types is further integrated to
form a single kernel matrix using a multiple kernel learning approach. Several
methods are suggested for integrating the kernels [10]. We take a two-step
approach that first combines the kernels in a weighted linear fashion and then
perform learning on the combined kernel. The kernel combination is defined as
follows:
Kβ(xi,xj) =
S∑
s=1
βsks(φ(x
s
i ), φ(x
s
j))
subjected to βs ≥ 0 and
S∑
s=1
βs = 1,
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where S is the number of kernels, xsi is the original feature vector of kernel s of
sample i, and βn is the kernel coefficient of kernel s.
To obtain optimal weights for kernel combination, we take the optimization
approach suggested by Zien et al. [47]. In their approach, the kernel coefficient is
determined by the efficacy of each of the kernel matrix containing sets learned by
Least Square Support Vector Machine (LS-SVM). LS-SVMs are closely related
to regularization networks and Gaussian processes but additionally emphasize
and exploit primal-dual interpretations from the optimization theory [31]. The
primal form of a LS-SVM is optimized by the following minimization problem:
min
w,b,err
(
1
2
wTw + γ
N∑
i=1
err2i )
subjected to yi[w
Tφ(xi) + b] = 1− err2i for i = 1, 2, . . . , N
where w is the weight vector we are trying to learn, errs is the error variables
that represent the value corresponding to misclassification in case of overlapping
distribution, and γ is the regularization parameter that tackles data over fitting
problem.
The standard multiple kernel learning approach constructs the base kernels
for each data type and determine their optimal kernel coefficient by solving
Equation 2.4 [42, 41].
min
β,w,b,err
(
1
2
S∑
s=1
βwTw + γ
N∑
i=1
err2i )
w.r.t. wk ∈ <Dk , err ∈ <N
subjected to

yi(
S∑
s=1
βsw
T
s φk(xi) + b) = 1− err2i ,
erri ≥ 0 for i = 1, 2, . . . , N,
S∑
s=1
βs = 1, βs ≥ 0 for s = 1, 2, . . . , S.
The derived dual for the problem in Equation 2.4 [2]is given as
min δ −
S∑
s=1
αi
δ ∈ <, α ∈ <N
subjected to

0 ≤ α ≤ 1γ,
S∑
i=1
αiyi = 0
1
2
S∑
i,j=1
αiαjyiyjkk(xi, xj) ≤ δ, ∀ = 1, . . . ,K
The standard multiple kernel learning approach constructs the base kernels
for each data type, and determine their optimal kernel coefficient by solving
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Equation 2.4. Here, the optimization problem is solved using semi-defined lin-
ear programming. The dual for the problem is computed by considering the
problem (Dk), squaring the constraints δ, multiplying the constraints by
1
2 and
performing substitution as 12δ
2 7→ δ leads to dual form of multiple kernel learn-
ing Equation 2.4, here kk(xi, xj) =< φk(xi), φk(xj) >. This process uses trans-
ductive learning setting, where the kernel matrix is learned from data. Initially
labeled training data is used to learn the good embedding, which is later applied
to unlabeled test data. Considering semi-defined linear programming optimiza-
tion using SVM enables to handle the optimization of convex cost functions and
machine learning concerns, thus provides a powerful method for learning the
kernel matrix [16].
2.5 Stratification Using Kernel K-means
Stratification of patients can be done with clustering methods. We use kernel K-
means on the generated multiple kernel matrix for stratifying the ovarian cancer
to subtypes. The multiple kernel matrix contains the similarity information
about pairs of data in the combined feature space. Thus, when we apply the
kernel k-means to the multiple kernel matrix, data are clustered so that the
clustering error is minimized in the combined feature space. The objective
function of kernel k-means is defined as follows:
D({pic}kc=1) =
k∑
c=1
∑
xi∈pic
||φ(xi)−mc||2,where mc =
∑
xi∈pic
φ(xi)
|pic| ,
where pic denotes the clusters, {pic}kc=1 denotes a partitioning of points, mc
denotes the center of cluster pic, and |pic| denote the size of the cluster pic. The
Euclidean distance between the data point, φ(xi), and the cluster center, mc,
in the feature space is determined as follows [16]:
||φ(xi)−mc||= φ(xi)φ(xi)−
∑
xj∈pic
φ(xi)φ(xj)
|pic| +
∑
xj ,xl∈pic
φ(xj)φ(xl)
|pic|2
Here, the φ(xi)φ(xj) is computed using appropriate selected kernel functions.
2.6 Clinical Feature Prediction Process
We also use the learned multiple kernel matrix for predicting clinical outcomes.
For prediction, we again employ LS-SVM classifier. That is, using the multiple
kernel as input, we run the LS-SVM to predict the survival time and the tumor
grade of patients. The performance of the proposed model was evaluated on 312
samples in TCGA ovarian cancer data sets. Each of the samples contains sets
of molecular data with matched clinical information. We split the 312 sample
randomly so that 50% of the samples are assigned to the training set, 25% as-
signed to the validation set to learn the model parameters, and rest are assigned
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to the testing set to test the performance of the final model. For evaluations, we
calculate the accuracy of survival prediction and area under the curve (AUC) of
the receiver operating characteristic (ROC) curve for the tumor grade classifica-
tion. The curves were constructed by plotting true positive rate (Sensitivity) in
function of the false positive rate (100-Specificity) for different selected thresh-
old for the tumor grade parameter. We selected the threshold range from 0.2
to 0.9. Each point on the ROC curve denotes a sensitivity/specificity pair cor-
responding to a selected decision threshold. The area under the curve specifies
the ability of the test to correctly classify high grade and low grade tumor. The
AUC value is computed by a non-parametric method based on constructing
trapezoids under the curve as an approximation of area.
3 Results
We report the results of validation and performance of combining the clinical
features with the biological features by the multiple-kernel on two important
translational bioinformatics tasks: patient stratification and clinical predictions.
3.1 Patient Stratification via K-means
We performed the kernel k-means clustering to stratify ovarian cancer patients
using the generated kernel matrices. We compared four data type combinations
as input to the k-mean clustering: the first multiple kernel is constructed from
only the molecular data types listed in Table 1, the second is constructed from
clinical information (i.e., age, stage, grade), the third is constructed by a non-
weighted linear combination of kernels of molecular as well as clinical data, and
the fourth is construed by weighted linear combination of kernels of molecular
and clinical data.
To evaluate the clustering result, we performed survival analysis on each
cluster, or subgroups, using the Cox proportional hazards regression model in
the R survival package [35] for each of the data type combinations. Out of 312
patient samples, the clustering was carried out for 75% (231) of the samples and
25% (81) to determine the number of clusters, k.
The value of k (i.e., the number of clusters) was determined using the log
rank statistics. Figure 2 shows the different log rank statistic values obtained
for a different number of clusters. Figure 2 (A) shows the plot for integrated
molecular data indicating the best value for k is 5. Figure 2 (B) is a graph for
determining the k (i.e., 5) value for clinical data. Similarly, figure 2 (C) and
figure 2 (D) plots results when molecular data is integrated with clinical without
and with weighted kernel coefficient, results in best clusters for k=5 and k=6
respectively. We compared the survival times for these clusters using log-rank
statistics and obtained the P-value. The P-value for all the above cases is less
than 0.05. Thus, it shows that there exists a significant separation between the
subgroups with respect to survival time.
10
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Figure 2: Log rank statistic to determine the number of clusters (A) Molecular
data (B) Clinical data (C) Molecular and clinical data with non-weighted
linear kernel coefficient (D) Molecular and clinical data with weighted kernel
coefficient
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Figure 3: Kernel k-means clustering of the TCGA OV all molecular data
reveals (a) five molecular subtypes (clusters) (b) tumor grade for each subtype.
Setting k=5 in kernel k-means clustering, the p-value of the subtype sepa-
ration for survival analysis is 0.02 for all molecular data types (figure 3 (a)),
0.0079 for clinical data (figure 4 (a)), 0.009 for integrated molecular and clinical
data with non-weighted kernel coefficient (figure 5 (a)), 0.0014 for integrated
molecular and clinical data with weighted kernel coefficient (figure 6 (a)). It
can be observed that the clusters identified by integrating the clinical data are
more predictive with log-rank p-value of 1.4 x 10−3 . The size of the cluster
formed is not uniform, however, the method shows an ability to categorize the
patient samples into sub groups that significantly differ in the survival time. In
addition, to separating the patient according to survival time with significant
statistics the subgroups are correlated to tumor grade.
In addition to mean survival time the clusters also show resembles in two
other clinical features that are vitalstatus and neoplasmcancerstatus. The
vitalstatus status is categorized into two based on whether the patient current
state is deceased or living. Similarly, the neoplasmcancerstatus is grouped into
two patient samples with tumor or tumor free. Note that the missing field in
neoplasmcancerstatus is indicating the unavailability of information.
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Table 2: Patient stratification using molecular data
Cluster Size Avg. age
Vital status neoplasm cancer status
Deceased Living With tumor Tumor free Missing
1 33 61.24 13 (39.39) 20 (60.61) 18 (54.54) 11 (33.33) 4 (12.12)
2 48 56.96 27 (56.25) 21 (43.75) 27 (56.25) 10 (20.83) 11 (22.92)
3 50 60.34 31 (62.0) 19 (38.0) 37 (74.0) 10 (20.0) 3 (6.0)
4 47 62.47 34 (72.34) 13 (27.66) 36 (76.59) 6 (12.77) 5 (10.64)
5 53 59.87 31 (58.49) 22 (41.51) 30 (56.60) 17 (32.08) 6 (11.32)
Table 3: Patient stratification using clinical data
Cluster Size Avg. age
Vital status neoplasm cancer status
Deceased Living With tumor Tumor free Missing
1 50 49.28 30 (60.0) 20 (40.0) 30 (60.0) 14 (28.0) 6 (12.0)
2 64 71.22 38 (59.37) 26 (40.63) 39 (60.94) 17 (26.56) 8 (12.5)
3 45 68.24 27 (60.0) 18 (40.0) 30 (66.67) 9 (20.0) 6 (13.33)
4 72 52.61 51 (70.83) 31 (43.05) 49 (68.06) 14 (19.44) 9 (12.5)
Table 4: Patient stratification with linear kernel weights using molecular data
and clinical data
Cluster Size Avg. age
Vital status neoplasm cancer status
Deceased Living With tumor Tumor free Missing
1 46 55.07 0 (0.0) 46 (100) 15 (32.61) 25 (54.35) 6 (13.04)
2 30 59.23 0 (0.0) 30 (100) 12 (40.0) 15 (50.0) 3 (10.0)
3 108 60.74 108 (100) 0 (0.0) 91 (84.26) 4 (3.70) 13 (12.04)
4 24 63.29 24 (100) 0 (0.0) 22 (91.67) 0 (0.0) 2 (8.33)
5 23 64.87 4 (17.39) 19 (82.61) 8 (34.78) 10 (43.48) 5 (21.74)
Table 5: Patient stratification with optimized kernel weights using molecular
data and clinical data
Cluster Size Avg. age
Vital status Neoplasm cancer status
Deceased Living With tumor Tumor free Missing
1 15 59.53 1 (6.67) 14 (93.33) 4 (26.67) 10 (66.67) 1 (6.67)
2 19 63 19 (100) 0 (0.0) 17 (89.47) 0 (0.0) 2 (10.53)
3 37 67.38 37 (100) 0 (0.0) 33 (89.19) 0 (0.0) 4 (10.81)
4 52 56.60 52 (100) 0 (0.0) 41 (78.85) 3 (5.76) 8 (15.38)
5 81 58.09 0 (0.0) 81 (100) 29 (35.80) 40 (49.38) 12 (14.81)
6 27 61.11 27 (100) 0 (0.0) 24 (88.89) 1 (3.70) 2 (7.41)
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Figure 4: Kernel k-means clustering for clinical data
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Figure 5: Kernel k-means clustering of the TCGA OV all molecular data with
clinical data with linear kernel combination reveals (a) five molecular subtypes
(clusters) (b) tumor grade for each subtype.
It is observed that the combined molecular data and clinical data although
are able to carry out a clear distinction between clusters in terms of mean sur-
vival time but lack the distinction in terms of vitalstatus and neoplasmcancerstatus
summarize in Table 2 and Table 3 respectively. On the other hand, the results
obtained when the clinical data is combined with molecular data are different
as reported in Table 4 and Table 5. Table 4 shows results for the linear combi-
nation of kernels. It is observed that a distinct stratification can be obtained for
the vitalstatus , but not in the case of neoplasmcancerstatus. Table 5 reports
the results with optimized kernel coefficient used to form the kernel matrix. It is
observed that the stratification of the patients is more clear for both vitalstatus
and neoplasmcancerstatus.
3.2 Clinical Outcome Prediction using Molecular Data
The observations from patient stratification section motivate us to consider in-
tegrated molecular data, clinical data, and their combinations. The model is
evaluated on a set of dichotomized overall prediction using an LS-SVM. We
carry out a prediction for two characteristic feature survival risk and tumor
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Figure 6: Kernel k-means clustering of the TCGA OV all molecular data with
clinical data with optimized weights reveals (a) six molecular subtypes
(clusters) (b) tumor grade for each subtype.
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Figure 7: Area under curve for high v.s. low grade classification of OV
grade. The survival risk is divided into two based on high risk and low risk
periods. The high risk considers cases where the survival time is lower than
median survival time, whereas, low risk considers cases where survival time is
higher than median. For the selected samples from TCGA data the median
survival time is set to 998 days. We also perform prediction on high and low
grade tumor using molecular data, clinical data and their combinations. The
low grade contains samples with tumor grade of type G1 or G2 whereas, high
grade contains samples corresponding to type G3 and G4 [22] .
Figure 7 shows the performance behavior of the model summary of the pre-
diction when molecular data are considered in isolation and when all molecular
data and clinical features are integrated. It is observed that high AUC values of
0.8217, 0.8449, 0.8538, 0.8718 and 0.8937 are obtained for CNA, methylation,
clinical, non-weighted integrated combination and weighted integrated data re-
spectively. These observations also help us to infer some biological information.
For the patient samples, in which the changes in tumor samples are due to
the structural variation in the chromosome like a copy number variation or
methylation seems to have a slightly higher influence on high or low grade clin-
ical predictions. The tumor samples with functional changes like mutation and
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Table 6: Patient survival risk prediction with individual data types.
Data types TP FP TN FN Spec. Sens. Acc.
CNA 0.6904 0.3095 0.7368 0.2632 74.36 68.29 71.25
Mutation 0.6667 0.3333 0.7105 0.2895 71.79 65.85 68.75
Methylation 0.6905 0.3095 0.7105 0.2895 72.5 67.5 70
mRNA 0.6428 0.3571 0.6842 0.3158 69.23 63.41 66.25
Clinical 0.7143 0.2857 0.73684 0.2632 75.0 70.0 72.5
CNA+Mutation+mRNA
Methylation 0.7381 0.2619 0.7368 0.2632 75.61 71.79 73.75
Table 7: Pateint survival risk prediction with individual data types and
clinical.
Data types TP FP TN FN Spec. Sens. Acc.
CNA+clinical 0.7143 0.2857 0.7368 0.2632 75 70 72.5
Mutation+clinical 0.6667 0.3333 0.7368 0.2632 73.68 66.67 70
Methylation+clinical 0.7143 0.2857 0.7105 0.2895 73.17 69.23 71.25
mRNA+clinical 0.6429 0.3571 0.7368 0.2632 72.97 65.12 68.75
CNA+Mutation+Methylation
+mRNA+Clinical 0.7619 0.2381 0.7632 0.2368 78.05 74.36 76.25
mRNA also directly relate and contribute towards the classification of clinical
outcome. For the developed model, methylation performed better in compari-
son to other molecular data. Overall, the integration of the different data types
improved the prediction accuracy.
The results for high risk and low risk survival are summarized in Table 6
and Table 7 with accuracy as the performance measure. The notation used in
these tables are TP stands for a true positive, FP stands for a false positive, TN
for a true negative, FN for a false negative, Spec. for specificity and Sens. for
sensitivity. The accuracy is the proportion of true results (both true positives
and true negatives) among the total number of cases examined. Table 6 reports
the results for molecular data and their integration. It summarizes the behavior
of individual data set in prediction accuracy. Amongst the individual molecular
data CNA is able to predict low risk and high risk patient for nearly 71% of the
samples. Next, in order to determine the behavior of data type when integrated
with clinical data experimentation were carried out, the results are reported in
Table 7. The results show an overall increase in accuracy by integration: for the
low risk vs. high risk survival classification. These findings are useful as they
suggest that some biological information may be fused to various data sources
from different genomic levels. Thus, integration of these independent data types
increases the chances of success in cancer outcome predictions.
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4 Conclusion
In this paper, we have developed a multiple kernel learning based pipeline for
integrative analysis of heterogenous data types and apply it on ovarian cancer
data. The data types we examined are molecular data and clinical data. The
model is used to carry out patient stratification and clinical outcome prediction.
We use kernel k-means to perform stratification of patients and examine inter-
cluster dissimilarity of survival time, vitalstatus and neoplasmcancerstatus.
Stratification is done considering different test cases including integrated molec-
ular data, clinical data, integration using linear non-weighted combination and
integration using weighted kernel coefficient combination. The patient strati-
fication results for different test cases show that the integration of molecular
and clinical data results in a better pattern forming relation. The clinical out-
come prediction is done for tumor grade and survival risk. In the case of tumor
grade, a better AUC of 0.8937 was achieved for weighted kernel combination in
comparison to 0.8538 considering only clinical data. For survival risk prediction
it was observed that when molecular data are integrated with clinical data the
overall prediction of the system is improved. This work concludes that integra-
tion of molecular data along with clinical data not only helps in carrying out
better patient stratification but also improves the prediction accuracy of the
model.
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